Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York.
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York; Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California.
J Am Acad Dermatol. 2019 Jul;81(1):163-172. doi: 10.1016/j.jaad.2019.03.043. Epub 2019 Mar 21.
Prescription medications are among the most common causes of sexual dysfunction, and patients are often hesitant to seek help when experiencing these symptoms.
In this review, we identify the available evidence of sexual adverse effects in men using systemic dermatologic medications and suggest screening protocols and actions that may improve a patient's symptoms where possible.
A systematic review was conducted of all articles in the PubMed database published from the time of inception to May 2018 to identify studies evaluating the use of systemic dermatologic medications in men with evidence of sexual adverse effects. Subsequently, a secondary in-depth literature review was performed for each individual medication.
There were 5497 articles reviewed in the primary systematic review, and 59 articles covering 11 systemic dermatologic medications met inclusion criteria. We identified level 1 evidence for sexual adverse effects as a primary outcome in patients taking finasteride.
Many included studies were limited by sample size and methodology.
The information in this review may serve as a reference of adverse effects when deciding on a therapeutic agent and a guide to help identify patients to screen for sexual dysfunction.
处方药物是导致性功能障碍的最常见原因之一，而当患者出现这些症状时，往往会犹豫不决，不愿寻求帮助。
在本综述中，我们确定了男性使用全身性皮肤科药物时出现的性不良反应的现有证据，并提出了可能改善患者症状的筛查方案和措施。
对 PubMed 数据库中从成立到 2018 年 5 月发表的所有文章进行系统综述，以确定评估男性使用全身性皮肤科药物与性不良反应证据的研究。随后，对每种药物进行了二次深入文献综述。
在最初的系统综述中，共回顾了 5497 篇文章，有 59 篇涵盖 11 种全身性皮肤科药物的文章符合纳入标准。我们确定了服用非那雄胺的患者出现性不良反应这一主要结局的 1 级证据。
许多纳入的研究受到样本量和方法的限制。
本综述中的信息可以作为在选择治疗药物时参考不良反应的依据，并为识别需要筛查性功能障碍的患者提供指导。
